Heavy marriage! Baiji Shenzhou announced the global tumor strategic cooperation and equity investment with Amgen, and Amgen invested 20 billion yuan!

January 4, 2020 / BIOON / -- beigene is a biomedical company in the commercial stage, focusing on the development and commercialization of innovative molecular targeting and tumor immune drugs for cancer treatment Recently, the company announced that the global tumor strategic cooperation with Amgen on October 31, 2019 has been approved by the company's shareholders and meets other transaction conditions, and the cooperation has officially come into effect At the same time, Amgen has completed the acquisition of about 20.5% shares in Baiji Shenzhou According to the terms of cooperation, Baiji Shenzhou will be responsible for the commercialization and development in China of three cancer drugs approved or declared by Amgen, i.e agavir ® (xgeva ®) desurmab injection, kyprolis ® kafzomib for injection, and blincyto ® betrimoxazole for injection Baiji Shenzhou and Amgen will cooperate to develop 20 Amgen anti-tumor pipeline drugs under research, among which Baiji Shenzhou will be responsible for the development and commercialization in China Amgen purchased 15895001 Baiji Shenzhou ADSS (representing 206635013 common shares) with cash value of about $2.8 billion In addition, Baiji Shenzhou also announced that Mr Anthony C Hooper, former executive vice president of Amgen global business operations, was elected as a member of the board of directors of the company according to the relevant agreement on share acquisition, effective today Mr Hooper joined Amgen as executive vice president of global business operations in October 2011 and retired from the company until August 2018 Prior to that, Mr Hooper served for 15 years at Bristol Myers Squibb, most recently as senior president of global business operations and President of its pharmaceutical industry in the Americas, Japan and intercontinental regions Mr Hooper's previous work experience includes assistant vice president of global marketing at Wyeth and the international marketing department in charge of Lederle international Mr Ou Lei Qiang, chairman, founder and CEO of Baiji Shenzhou, said: "we are very pleased to start the development of Amgen's important anti-tumor drugs and product pipeline to help patients around the world who may benefit from these drugs Through this strategic cooperation, we also warmly welcome Tony Hooper to join the board of directors Tony is committed to serving patients He has accumulated many years of commercial experience in large-scale enterprises, which can help Baiji Shenzhou's next enterprise growth and business operation expansion " Mr Hooper commented: "based on the background of Chinese medicine reform, bajishenzhou has created a unique global model for the development of new cancer drugs, which can have a positive impact on the pharmaceutical industry and patients After spending some time with the baiji Shenzhou team, I was deeply impressed by their insight, creativity and firm belief in bringing high-quality treatment programs to patients " ——Xgeva (angavir ®, desurmab): it has been approved by the State Drug Administration of China (nmpa) in May 2019 for the treatment of adult patients with giant cell tumor of bone who can not be removed surgically or who may cause serious dysfunction and young people with mature bone development The drug is a new type of RANKL inhibitor developed by Amgen It is a humanized monoclonal IgG2 antibody of RANKL It has high affinity and specificity for soluble and transmembrane human RANKL In patients with giant cell tumor of bone, the inhibition of RANKL secreted by tumor stromal components by desurmab can significantly reduce or eliminate osteoclast like tumor related giant cells Therefore, osteolysis is reduced, giant cell tumor progress is slowed down, and proliferative matrix is replaced by dense non proliferative and differentiated woven new bone, so as to improve the clinical outcome Desurmab can be used as a targeted therapy for giant cell tumor of bone, and may become an important treatment option to fill the unmet medical needs of this disease The main supporting clinical data provided by the applicant are obtained overseas The State Food and Drug Administration approved the listing of the product on May 21, and required the applicant to continue the clinical research in China after the approval of the product, and formulate and strictly implement the risk management plan ——Kyperolis (kafezomi): it is the second generation of proteasome inhibitor developed by Amgen, and has been approved for the treatment of multiple myeloma (mm) Proteasome plays an important role in cell function and growth, and can degrade damaged or no longer needed proteins The mechanism of action of the drug is that it can block proteasome and lead to excessive accumulation of protein in cells In some cells, the drug can cause cell death, especially MM cells, because these cells contain a large number of abnormal proteins, so the effect of the drug on mm death is particularly obvious In the United States, approved indications of the drug include: (1) combination with dexamethasone or combination with lenalidomide and dexamethasone for relapsed / refractory MM patients who have previously received 1-3 therapies; and (2) as a single drug therapy for relapsed / refractory MM patients who have previously received one or more therapies Since its first approval in 2012, about 130000 patients worldwide have received kyrolis treatment In China, the listing application of kyrolis was undertaken by the drug evaluation center (CDE) of the State Food and Drug Administration on November 30, 2019 ——Blincyto: It is the first cd19-cd3 bispecific T cell convergence (bite) immunotherapy approved in the world It is also the first bispecific antibody product born on the bite technology platform One end of the product combines with the CD19 antigen expressed on the surface of B cells, and the other end combines with the CD3 receptor on the surface of T cells, which can collect T cells to the vicinity of cancer cells and promote the killing of cancer cells Blincyto is the first drug approved by FDA to destroy leukemic cells through human T cells At present, it has been approved for the following indications: (1) treatment of children and adults with relapsed / refractory precursor B-cell acute lymphoblastic leukemia (pre-B all); (2) positive for minimal residual disease (MRD ≥ 0.1%) after the first or second complete remission All children and adults, MRD eradication In all patients, the detection of residual cancer cells (MRD) after complete remission is the strongest prognostic factor for the assessment of relapse In China, Amgen submitted blincyto's listing application on October 29, 2019, with the acceptance number of jxss1900060 Original source: Baiji Shenzhou